Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Madrigal Pharmaceuticals (MDGL) Assets Average (2019 - 2025)

Historic Assets Average for Madrigal Pharmaceuticals (MDGL) over the last 14 years, with Q3 2025 value amounting to $1.2 billion.

  • Madrigal Pharmaceuticals' Assets Average rose 942.38% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 942.38%. This contributed to the annual value of $841.4 million for FY2024, which is 6775.62% up from last year.
  • Latest data reveals that Madrigal Pharmaceuticals reported Assets Average of $1.2 billion as of Q3 2025, which was up 942.38% from $1.0 billion recorded in Q2 2025.
  • Madrigal Pharmaceuticals' 5-year Assets Average high stood at $1.2 billion for Q3 2025, and its period low was $187.5 million during Q3 2022.
  • Moreover, its 5-year median value for Assets Average was $318.8 million (2021), whereas its average is $569.7 million.
  • Its Assets Average has fluctuated over the past 5 years, first crashed by 4072.0% in 2022, then skyrocketed by 30210.09% in 2024.
  • Madrigal Pharmaceuticals' Assets Average (Quarter) stood at $289.0 million in 2021, then decreased by 9.83% to $260.6 million in 2022, then skyrocketed by 68.55% to $439.3 million in 2023, then skyrocketed by 140.81% to $1.1 billion in 2024, then increased by 12.4% to $1.2 billion in 2025.
  • Its Assets Average stands at $1.2 billion for Q3 2025, versus $1.0 billion for Q2 2025 and $1.0 billion for Q1 2025.